aTYR PHARMA (ATYR) Change in Accured Expenses (2014 - 2026)

aTYR PHARMA (ATYR) has reported Change in Accured Expenses for 13 consecutive years, with -$266000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses fell 105.53% year-over-year to -$266000.0; the trailing twelve-month figure through Jun 2026 stood at -$4.3 million (down 219.65% YoY), and the FY2025 full-year result was -$33000.0, up 97.54% from the prior year.
• Change in Accured Expenses grew to -$266000.0 in Q2 2026 per ATYR's latest filing, from -$3.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.8 million in Q2 2025 and bottomed at -$4.3 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $272111.1 across 5 years, with a median of $127000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 935.0% in 2022, then slumped 11097.37% in 2024.
• Over 5 years, Change in Accured Expenses stood at $1.9 million in 2022, then soared by 81.86% to $3.4 million in 2023, then tumbled by 75.65% to $825000.0 in 2024, then plunged by 164.97% to -$536000.0 in 2025, then jumped by 50.37% to -$266000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$266000.0, -$3.5 million, and -$536000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.